These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28455524)

  • 1. Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models.
    Schreiber J; Grimbergen LA; Overwater I; Vaart TV; Stedehouder J; Schuhmacher AJ; Guerra C; Kushner SA; Jaarsma D; Elgersma Y
    Sci Rep; 2017 Apr; 7(1):1256. PubMed ID: 28455524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.
    Gripp KW; Sol-Church K; Smpokou P; Graham GE; Stevenson DA; Hanson H; Viskochil DH; Baker LC; Russo B; Gardner N; Stabley DL; Kolbe V; Rosenberger G
    Am J Med Genet A; 2015 Sep; 167A(9):2085-97. PubMed ID: 25914166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations.
    Gripp KW; Lin AE
    Genet Med; 2012 Mar; 14(3):285-92. PubMed ID: 22261753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models.
    Dard L; Hubert C; Esteves P; Blanchard W; Bou About G; Baldasseroni L; Dumon E; Angelini C; Delourme M; Guyonnet-Dupérat V; Claverol S; Fontenille L; Kissa K; Séguéla PE; Thambo JB; Nicolas L; Herault Y; Bellance N; Dias Amoedo N; Magdinier F; Sorg T; Lacombe D; Rossignol R
    J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
    Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
    Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model.
    Tidyman WE; Goodwin AF; Maeda Y; Klein OD; Rauen KA
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34553752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased osteoclastogenesis contributes to bone loss in the Costello syndrome
    Nandi S; Chennappan S; Andrasch Y; Fidan M; Engler M; Ahmad M; Tuckermann JP; Zenker M; Cirstea IC
    Front Cell Dev Biol; 2022; 10():1000575. PubMed ID: 36330334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studying Metabolic Abnormalities in the Costello Syndrome HRAS G12V Mouse Model: Isolation of Mouse Embryonic Fibroblasts and Their In Vitro Adipocyte Differentiation.
    Fidan M; Chennappan S; Cirstea IC
    Methods Mol Biol; 2021; 2262():397-409. PubMed ID: 33977491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome.
    Wey M; Lee J; Jeong SS; Kim J; Heo J
    Biochemistry; 2013 Nov; 52(47):8465-79. PubMed ID: 24224811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
    Niihori T; Aoki Y; Okamoto N; Kurosawa K; Ohashi H; Mizuno S; Kawame H; Inazawa J; Ohura T; Arai H; Nabatame S; Kikuchi K; Kuroki Y; Miura M; Tanaka T; Ohtake A; Omori I; Ihara K; Mabe H; Watanabe K; Niijima S; Okano E; Numabe H; Matsubara Y
    J Hum Genet; 2011 Oct; 56(10):707-15. PubMed ID: 21850009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies.
    Papale A; d'Isa R; Menna E; Cerovic M; Solari N; Hardingham N; Cambiaghi M; Cursi M; Barbacid M; Leocani L; Fasano S; Matteoli M; Brambilla R
    Biol Psychiatry; 2017 Feb; 81(3):179-192. PubMed ID: 27587266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.
    Klüppel M; Samavarchi-Tehrani P; Liu K; Wrana JL; Hinek A
    Eur J Hum Genet; 2012 Aug; 20(8):870-7. PubMed ID: 22317973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A very mild phenotype in six individuals of a three-generation family with the novel HRAS variant c.176C > G p.(Ala59Gly): Emergence of a new HRAS-related RASopathy distinct from Costello syndrome.
    Frey T; Ivanovski I; Bahr A; Zweier M; Laube J; Luchsinger I; Steindl K; Rauch A
    Am J Med Genet A; 2023 Aug; 191(8):2074-2082. PubMed ID: 37194190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
    Gremer L; De Luca A; Merbitz-Zahradnik T; Dallapiccola B; Morlot S; Tartaglia M; Kutsche K; Ahmadian MR; Rosenberger G
    Hum Mol Genet; 2010 Mar; 19(5):790-802. PubMed ID: 19995790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costello syndrome model mice with a Hras
    Katata Y; Inoue SI; Asao A; Kobayashi S; Terui H; Inoue-Shibui A; Abe T; Niihori T; Aiba S; Ishii N; Kure S; Aoki Y
    Cell Death Dis; 2020 Aug; 11(8):617. PubMed ID: 32792500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive, adaptive, and behavioral functioning of individuals with Costello syndrome: a review.
    Axelrad ME; Schwartz DD; Katzenstein JM; Hopkins E; Gripp KW
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):115-22. PubMed ID: 21495179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
    Levin MD; Saitta SC; Gripp KW; Wenger TL; Ganesh J; Kalish JM; Epstein MR; Smith R; Czosek RJ; Ware SM; Goldenberg P; Myers A; Chatfield KC; Gillespie MJ; Zackai EH; Lin AE
    Am J Med Genet A; 2018 Aug; 176(8):1711-1722. PubMed ID: 30055033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling.
    Titus HE; López-Juárez A; Silbak SH; Rizvi TA; Bogard M; Ratner N
    Glia; 2017 Dec; 65(12):1990-2002. PubMed ID: 28856719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.
    Goodwin AF; Tidyman WE; Jheon AH; Sharir A; Zheng X; Charles C; Fagin JA; McMahon M; Diekwisch TG; Ganss B; Rauen KA; Klein OD
    Hum Mol Genet; 2014 Feb; 23(3):682-92. PubMed ID: 24057668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic spectrum of Costello syndrome individuals harboring the rare HRAS mutation p.Gly13Asp.
    Bertola D; Buscarilli M; Stabley DL; Baker L; Doyle D; Bartholomew DW; Sol-Church K; Gripp KW
    Am J Med Genet A; 2017 May; 173(5):1309-1318. PubMed ID: 28371260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.